Shield Therapeutics (LON:STX) Sets New 1-Year Low at $1.50

Shield Therapeutics plc (LON:STXGet Free Report) reached a new 52-week low during trading on Monday . The company traded as low as GBX 1.50 ($0.02) and last traded at GBX 1.54 ($0.02), with a volume of 1817725 shares changing hands. The stock had previously closed at GBX 1.50 ($0.02).

Shield Therapeutics Stock Down 4.9 %

The business has a fifty day moving average of GBX 2.88 and a 200 day moving average of GBX 5.20. The firm has a market cap of £11.34 million, a P/E ratio of -12.29 and a beta of 0.84. The company has a quick ratio of 2.16, a current ratio of 2.95 and a debt-to-equity ratio of 21.30.

Shield Therapeutics Company Profile

(Get Free Report)

Shield Therapeutics plc, a specialty pharmaceutical company, focuses on commercialization of pharmaceuticals to treat unmet medical needs. Its lead product is Accrufer/Feraccru, a non-salt based oral therapy for adults to treat the iron deficiency with or without anemia. Shield Therapeutics plc was founded in 2008 and is based in Gateshead, the United Kingdom.

Read More

Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.